Pioglitazone
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Pioglitazone: From Type 2 Diabetes to Opsismodysplasia
One-Sentence Summary
Pioglitazone is a thiazolidinedione (TZD)-class PPAR-γ agonist and insulin sensitizer, established for treating type 2 diabetes mellitus. The TxGNN model's top-ranked prediction is Opsismodysplasia, a rare skeletal dysplasia, with a 99.59% prediction score but 0 clinical trials and 0 publications supporting this direction — the accompanying mechanistic review explicitly found no known biological link between pioglitazone's pathway and this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (established pharmacological use; not captured in evidence pack fields — Data Gap DG002) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for pioglitazone is not available in this evidence pack (Data Gap DG002). Based on established pharmacological knowledge, pioglitazone is a thiazolidinedione-class PPAR-γ agonist that improves insulin sensitivity, and its efficacy in type 2 diabetes is well documented.
Opsismodysplasia, however, is a rare skeletal dysplasia caused by mutations in INPPL1 (SHIP2), affecting skeletal development. The evidence pack's own mechanistic review states explicitly that there is no known biological relationship between pioglitazone's PPAR-γ/insulin-sensitizing pathway and the INPPL1-driven pathophysiology of this disease.
The high TxGNN score (99.59%) reflects similarity within the model's graph embedding space rather than a validated mechanistic or clinical association. With zero supporting trials or literature, this candidate should be treated as a hypothesis-generating signal only, not a mechanistically grounded repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Pioglitazone currently has no marketing authorization on record in New Zealand (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information. Note: the TFDA/regulatory package insert (warnings and contraindications) is flagged as a Blocking data gap (DG001) in this evidence pack, meaning a formal safety initial evaluation (S1) cannot currently proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Opsismodysplasia) has no supporting clinical trials or literature and an explicitly refuted mechanistic link, placing it at evidence level L5 (model prediction only). Separately, a blocking data gap (DG001 — missing TFDA warnings/contraindications) prevents any safety pre-assessment regardless of efficacy signal strength.
To proceed, the following is needed:
- TFDA/regulatory package insert data (warnings, contraindications) — resolves DG001 (Blocking)
- Confirmed mechanism-of-action documentation — resolves DG002
- Disease-specific preclinical or mechanistic evidence directly linking PPAR-γ agonism to opsismodysplasia pathophysiology
- If pursuing alternative candidates from this batch (e.g., lipodystrophy-spectrum diseases, where PPAR-γ's role in adipocyte differentiation offers a more plausible rationale), targeted literature search and expert mechanistic review before advancing past S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.